Please assess the completion status of the following clinical trial:

Trial Title: HIV Persistence and Viral Reservoirs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years, and~2. HIV infection, and~3. Antiretroviral-naïve, and~4. CD4+ T cell count \>350 cells/mm3, and~5. Controllers: antiretroviral untreated with 50-1000 copies/mL viral load for at least 12 months~Exclusion criteria:~1. Persons with known rheumatologic conditions (e.g., systemic lupus erythematosus), because of their predilection for biologic false-positive testing on HIV antibody tests.~2. Screening absolute neutrophil count \<1,000 cells/mm3, platelet count \<70,000 cells/mm3, hemoglobin \< 8 mg/dL, estimated creatinine clearance \<40 mL/minute, aspartate aminotransferase \>100 units/L, alanine aminotransferase \>100 units/L.~3. Screening genotype resistance testing showing resistance to tenofovir or emtricitabine.~4. Known kidney disease.~5. Known bone disease, including pathologic fractures.~6. Patients with chronic Hepatitis B infection, because of the risk of liver abnormalities after starting and stopping tenofovir/emtricitabine.~7. Concurrent treatment with lamivudine, adefovir, entecavir, or telbivudine.~8. Serious illness requiring hospitalization or parental antibiotics within the preceding 3 months.~9. Any vaccination 2 weeks prior to baseline (Day 0) visit and throughout the study period. NOTE: Because the study will most likely be actively recruiting during the influenza season, all subjects will be encouraged to receive their annual influenza vaccine at the screening visit (4 weeks prior to baseline \[Day 0\] visit) if they have not already been vaccinated for the 2009-10 season and if it is medically indicated.~10. Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drug in the preceding 16 weeks (e.g. corticosteroid therapy equal to or exceeding a dose of 15 mg/day of prednisone for more than 10 days, IL-2, interferon-alpha, methotrexate, cancer chemotherapy). NOTE: Use of inhaled or nasal steroid use is not exclusionary.~11. Concurrent treatment with phenobarbital, phenytoin, or rifampin.~12. Pregnant or breastfeeding women. Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Elite controller (Type: EXPERIMENTAL): Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).